[go: up one dir, main page]

WO1997038706A1 - Composes glycopeptidiques - Google Patents

Composes glycopeptidiques Download PDF

Info

Publication number
WO1997038706A1
WO1997038706A1 PCT/US1997/005735 US9705735W WO9738706A1 WO 1997038706 A1 WO1997038706 A1 WO 1997038706A1 US 9705735 W US9705735 W US 9705735W WO 9738706 A1 WO9738706 A1 WO 9738706A1
Authority
WO
WIPO (PCT)
Prior art keywords
independently
formula
alkylene
loweralkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/005735
Other languages
English (en)
Inventor
Douglas R. Stack
Richard C. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to JP53716797A priority Critical patent/JP4159110B2/ja
Priority to CA002251086A priority patent/CA2251086C/fr
Priority to US09/125,496 priority patent/US6037447A/en
Priority to AU26092/97A priority patent/AU2609297A/en
Publication of WO1997038706A1 publication Critical patent/WO1997038706A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention is directed to certain glycopeptide dimers in which two glycopeptide units are covalently linked to one another through their disaccharide amine, via a linking radical.
  • This invention is also directed to the monomeric intermediates. All of these compounds are useful as antibacterials, especially for the control of gram positive bacteria; the compounds are particularly useful for the control of resistant bacterial strains, such as vancomycin-resistant-enterococci ("VRE") .
  • VRE vancomycin-resistant-enterococci
  • each of G and G' is independently selected from the group consisting of deshydrovancomycin of the formula:
  • Y 1 is OH or ⁇ Y 2 and Y 2 is defined as follows:
  • each Y 2 independently represents hydrogen, alkyl of Ci-Cio, cycloalkyl of C 5 -C 6 .
  • each Y 5 is independently hydrogen or loweralkyl of C 1 -C 4 , or Y 4 is phenyl or phenyl substituted with from one to three substituents, each of which is independently halo, nitro, loweralkyl of C 1 -C 4 , cycloalkyl of C 5 -C 6 ; loweralkoxy of C 1 -C 4 , haloloweralkyl of C 1 -C 4 , or haloloweralkoxy of C 1 -C 4 ; or
  • one Y 2 is hydrogen and the other Y 2 is (2-furanon-3-yl) ; or (3) both Y s are taken together with the nitrogen and constitute a five- to seven-membered heterocyclic ring optionally containing in addition to the indicated nitrogen atom one additional hetero ring atom which is nitrogen, oxygen, or sulfur, and which heterocyclic radical can be unsubstituted or substituted with from one or two substituents, each of which is loweralkyl of C 1 -C 2 , loweralkoxy of C 1 -C 2 , phenyl, benzyl, or C ⁇ -C 6 -alkanoyl; and L is a divalent linking radical of the formula A:
  • A is: alkylene of C 1 -C16, (alkylene of C 1 -C 4 -X' ) q -alkylene of C 1 -C4, wherein q is 1-3
  • alkylene of of Ci -C 2 or
  • each R independently represents halo, loweralkyl of C ⁇ -C ⁇ ,, loweralkoxy of C 3. -C 6 , phenyl, or phenyl substituted by from 1 to 2 substituents, each of which is independently halo, loweralkyl of C ⁇ -C 6 ⁇ or loweralkoxy of Ci-C ⁇ ; each X is independently -O- or -N- wherein R 2 is H or loweralkyl of
  • each X' is independently -0-, -S-, or -N- wherein R 2
  • R 2 is as defined above; or L is a divalent linking radical of the formula B:
  • X represents alkylene of C 1 -C 4 or a phenylene of the formula
  • R ⁇ "2 wherein R is as defined above; and each R 3 is independently CH 2 or 0.
  • the present invention also includes salts of the foregoing compounds.
  • glycopeptide units, G and G' may be identical or different.
  • linkage of the glycopeptide units is through the amine group of the disaccharide sugar.
  • Any "alkylene" of C 2 or higher can be straight chain or branched.
  • Antibacterial activity is enhanced by employing preferred "L” groups.
  • Preferences include the following, individually and in any combination:
  • the compounds of the present invention are prepared by reacting vancomycin or A82846B with a bisaldehyde of the formula:
  • the present condensation is typically conducted in a polar solvent, such as dimethylformamide or methanol, or a mixture of polar solvents.
  • a polar solvent such as dimethylformamide or methanol, or a mixture of polar solvents.
  • the reaction goes forward over a range of temperatures, such as from 25°C to 100°C, but is preferably conducted at temperatures of about 60°C to 70°C.
  • the reaction is preferably conducted under an inert atmosphere, such as nitrogen or argon.
  • G CH-L-CHO where only one aldehyde group has reacted with glycopeptide.
  • the Schiff base is subsequently reduced.
  • the reduction is conducted in the same reaction mixture in a polar solvent, and employing a chemical reducing agent.
  • Metal borohydrides such as sodium borohydride and sodium cyanobo-rohydride are preferred.
  • the reaction goes forward over a range of temperatures, such as from about 25°C to about 100°C; preferably, the reaction is conducted at about 60°C to 70°C.
  • dimer of Formula I a dimer of Formula I
  • a mono- substituted derivative of Formula II or a mixture of both.
  • both products are produced.
  • some control of the products can be achieved by the amount of reactants employed.
  • a dimer of Formula I requires two molecular proportions of vancomycin or A82846B per molecular proportion of bisaldehyde, whereas a compound of Formula II requires equimolar amounts of the reactants.
  • the reaction is continued through the reduction, and the respective products separated at that time.
  • the product, or mixture of products can be isolated and purified if desired in a conventional manner, such as by HPLC. Characterization of products is best accomplished by Fast Atom Bombardment Mass Spectroscopy (FAB «MS) .
  • compounds of the present invention can be prepared in an alternate route.
  • a dimer is prepared by the foregoing synthetic route, and further changes to the structure of the glycopeptide are made subsequently. This approach to synthesizing the present dimers is illustrated by
  • Elution was accomplished with a linear gradient of 5% CH 3 CN - 95% buffer to 80% CH 3 CN - 20% buffer over 30 minutes.
  • the buffer used was 0.5% triethylamine in water, adjusted to pH 3 with H3PO4.
  • the desired fractions were subsequently desalted with a Waters Ci ⁇ Sep-Pak (35 cc) followed by lyophilization.
  • a buffer containing 0.1% TFA in H 2 O can be used, in which case the TFA salt is obtained directly after lyophilization.
  • a dry 100 L round bottom flask was charged with A82846B-tri-acetate salt (278 mg, 0.157 mmol.), and 1,9-bis- (4 ' -formylphenoxy) -n-nonane (103.7 mg, 0.282 mmol.) .
  • Anhydrous DMF (15 mL) and anhydrous MeOH (15 mL) were added to the flask and the resulting mixture was stirred under N 2 and heated to 70°C. After 3.5 hours, sodium cyanoborohydride (68 mg, 1.08 mmol.) was added in one portion, and the reaction mixture was maintained at 70°C for one additional hour.
  • a dry flask was charged with A82846B-tri-acetate salt (5.0 g, 0.003 ol.), and 1, 8-bis (4 ' -for ylphenoxy) -n-octane (1.93 g, 0.006 mol.) .
  • Anhydrous DMF 300 mL
  • anhydrous MeOH 300 mL
  • sodium cyanoborohydride 0.76 g, 0.012 mol.
  • the present invention is directed to a method for controlling a bacterial infection in a host animal, typically a warm-blooded animal, which comprises administering to the host animal an effective, antibacterial amount of a compound of Formula I or II.
  • the compounds of the present invention can be used to control and treat infections due to various bacteria, but especially gram-positive bacteria.
  • the compounds are used to control and treat infections due to bacteria resistant to existing antibacterials. For example, certain bacteria are resistant to methicillin, and yet others are resistant to vancomycin and/or teicoplanin.
  • the present compounds provide a technique for controlling and treating infections due to such resistant bacterial species.
  • the compounds can be administered by any of the conventional techniques, including the oral route and parenteral routes such as intravenous and intramuscular.
  • the amount of compound to be employed is not critical and will vary depending on the particular compound employed, the route of administration, the severity of the infection, the interval between dosings, and other factors known to those skilled in the art. In general, a dose of from about 0.5 to about 100 mg/kg will be effective; and in many situations, lesser doses of from about 0.5 to about 50 mg/kg will be effective.
  • a compound of the present invention can be administered in a single dose, but in the known manner of antibacterial therapy, a compound of the present invention is typically administered repeatedly over a period of time, such as a matter of days or weeks, to ensure control of the bacterial infection.
  • a compound of the present invention is typically formulated for convenient delivery of the requisite dose. Therefore, in another embodiment, the present invention is directed to a pharmaceutical formulation comprising a compound of either Formula I or II, in combination with a pharmaceutically- acceptable carrier.
  • a pharmaceutical formulation comprising a compound of either Formula I or II, in combination with a pharmaceutically- acceptable carrier.
  • Such carriers are well known for both oral and parenteral routes of delivery.
  • a formulation will comprise a compound of the present invention in a concentration of from about 0.1 to about 90% by weight, and often from about 1.0 to about 3%.
  • TABLES 5 and 6 The minimal inhibitory concentrations (MICs) were determined using a standard broth micro-dilution assay.
  • TABLE 6 presents a comparison of the activity of illustrative compounds against representative vancomycin-resistant and vancomycin-sensitive enterococci (Ent rococcus faecium and Enterococcus faecalis. mean geometric MIC (mcg/mL) , as determined by the standard broth micro-dilution assay.
  • MICs minimal inhibitory concentrations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne certains dimères glycopeptidiques dans lesquels les deux unités glycopeptidiques sont liées l'une à l'autre par covalence au moyen de leur disaccharide amine via un radical de liaison. L'invention concerne également des intermédiaires monomères. Tous ces composés conviennent comme agents antibactériens, et particulièrement pour combattre une bactérie Gram positive; de tels composés conviennent particulièrement pour combattre les souches bactériennes résistantes telles que les entérocoques résistants à la vancomycine ou 'VRE' (Vancomycin-Resistant-Enterococci).
PCT/US1997/005735 1996-04-12 1997-04-07 Composes glycopeptidiques Ceased WO1997038706A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP53716797A JP4159110B2 (ja) 1996-04-12 1997-04-07 グリコペプチド化合物
CA002251086A CA2251086C (fr) 1996-04-12 1997-04-07 Composes glycopeptidiques
US09/125,496 US6037447A (en) 1996-04-12 1997-04-07 Glycopeptide compounds
AU26092/97A AU2609297A (en) 1996-04-12 1997-04-07 Glycopeptide compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1530096P 1996-04-12 1996-04-12
US60/015,300 1996-04-12
US3173596P 1996-11-25 1996-11-25
US60/031,735 1996-11-25

Publications (1)

Publication Number Publication Date
WO1997038706A1 true WO1997038706A1 (fr) 1997-10-23

Family

ID=26687203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/005735 Ceased WO1997038706A1 (fr) 1996-04-12 1997-04-07 Composes glycopeptidiques

Country Status (11)

Country Link
EP (1) EP0802199B1 (fr)
JP (1) JP4159110B2 (fr)
AT (1) ATE187460T1 (fr)
AU (1) AU2609297A (fr)
CA (1) CA2251086C (fr)
DE (2) DE69700894D1 (fr)
DK (1) DK0802199T3 (fr)
ES (1) ES2140184T3 (fr)
GR (1) GR3032834T3 (fr)
PT (1) PT802199E (fr)
WO (1) WO1997038706A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042476A1 (fr) * 1998-02-20 1999-08-26 Advanced Medicine, Inc. Nouveaux agents antibacteriens
SG90053A1 (en) * 1998-06-08 2002-07-23 Advanced Medicine Inc Novel anti-bacterial agents
US6518242B1 (en) 1998-02-20 2003-02-11 Theravance, Inc. Derivatives of glycopeptide antibacterial agents

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4549999A (en) * 1998-06-08 1999-12-30 Advanced Medicine, Inc. Novel polyene macrolide compounds and uses
US6710168B1 (en) 1999-05-19 2004-03-23 The Trustees Of The University Of Princeton Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same
JP2002520422A (ja) 1998-07-14 2002-07-09 プリンストン ユニバーシティ グリコペプチド抗生物質、グリコペプチド抗生物質のコンビナトリアルライブラリーおよびその作成方法
CN1249081C (zh) 1998-12-23 2006-04-05 施万制药 糖肽衍生物或含有它们的药物组合物
WO2000069893A1 (fr) 1999-05-19 2000-11-23 Merck & Co., Inc. Composes glycopeptidiques antibacteriens, compositions contenant de tels composes et procedes dans lesquels ils sont utilises
EP1818340A4 (fr) 2004-11-29 2009-02-25 Univ Nagoya Nat Univ Corp Derives monomeres antibiotiques de glycopeptides
EP1926780B1 (fr) 2005-09-22 2013-08-14 Medivas, LLC Formules de poly(ester amide) et de poly(ester uréthane) contenant des diesters de bis-( -amino)-diol et méthodes d'emploi
EP1933881B1 (fr) 2005-09-22 2019-03-13 Medivas, LLC Compositions polymères solides pour administration et méthodes d'utilisation de celles-ci
CN101397333A (zh) * 2007-09-27 2009-04-01 浙江医药股份有限公司新昌制药厂 去羟基万古霉素及其制备方法、和其药物组合物及其用途
WO2009081958A1 (fr) 2007-12-26 2009-07-02 Shionogi & Co., Ltd. Dérivé antibiotique de glycopeptide glycosylé
EP2260060A4 (fr) 2008-04-01 2013-01-16 Univ Cornell Sels de chitosane organosolubles et biomatériaux dérivés du chitosane préparés à partir desdits sels
US20140171357A1 (en) * 2011-03-24 2014-06-19 Seachaid Pharmaceuticals, Inc. Vancomycin derivatives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521335A (en) * 1983-07-13 1985-06-04 Smithkline Beckman Corporation Aglycone and pseudo-aglycones of the AAD 216 antibiotics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521335A (en) * 1983-07-13 1985-06-04 Smithkline Beckman Corporation Aglycone and pseudo-aglycones of the AAD 216 antibiotics

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042476A1 (fr) * 1998-02-20 1999-08-26 Advanced Medicine, Inc. Nouveaux agents antibacteriens
FR2778184A1 (fr) * 1998-02-20 1999-11-05 Advanced Medicine Inc Composes a liaisons multiples antibacteriens nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
US6518242B1 (en) 1998-02-20 2003-02-11 Theravance, Inc. Derivatives of glycopeptide antibacterial agents
US7067620B2 (en) 1998-02-20 2006-06-27 Theravance, Inc. Antibacterial agents
SG90053A1 (en) * 1998-06-08 2002-07-23 Advanced Medicine Inc Novel anti-bacterial agents

Also Published As

Publication number Publication date
EP0802199A3 (fr) 1997-11-05
DE69700894T4 (de) 2000-09-21
AU2609297A (en) 1997-11-07
ES2140184T3 (es) 2000-02-16
JP2000509030A (ja) 2000-07-18
DE69700894T2 (de) 2000-05-04
EP0802199B1 (fr) 1999-12-08
DE69700894D1 (de) 2000-01-13
DK0802199T3 (da) 2000-05-01
ATE187460T1 (de) 1999-12-15
PT802199E (pt) 2000-04-28
JP4159110B2 (ja) 2008-10-01
CA2251086C (fr) 2007-02-20
GR3032834T3 (en) 2000-07-31
CA2251086A1 (fr) 1997-10-23
EP0802199A2 (fr) 1997-10-22

Similar Documents

Publication Publication Date Title
EP0816378B1 (fr) Dérivés d'amides antibiotiques glycopeptidiques
EP0802199B1 (fr) Dimères liés covalemment d'antibiotiques glycopeptidiques
KR100388867B1 (ko) 글리코펩타이드항생제유도체
EP0801075B1 (fr) Dimères liés covalemment d'antibiotiques glycopeptidiques
FI112662B (fi) Menetelmä antibiootin A 40926 amidijohdannaisten valmistamiseksi
EP0881229B1 (fr) Hexapeptides alkylés aux propriétés antibiotiques
US6670446B1 (en) N1 modified glycopeptides
JP4150430B2 (ja) グリコペプチドのヘキサペプチド
JP4086326B2 (ja) グリコペプチドの尿素およびチオ尿素誘導体
US6037447A (en) Glycopeptide compounds
AU647122B2 (en) C63-amide derivatives of 34-de(acetylglucosaminyl)-34-deoxy- teicoplanin and their use as medicaments against bacteria resistant to glycopeptide antibiotics
HK1007884B (en) Glycopeptide antibiotic amide derivatives
EP0563062A1 (fr) Hexapeptides derives de l'aglucoteicoplanine, et procede de preparation.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09125496

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2251086

Country of ref document: CA

Ref country code: CA

Ref document number: 2251086

Kind code of ref document: A

Format of ref document f/p: F